Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
The Tumor Immunoenvironment
Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor Immunoenvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions.
Cancer Immunotherapy: Mechanisms of Cancer Immunity, Engineering Immune- Based Therapies and Developing Clinical Trials
Clinicians, patients and scientists, alike, have been battling cancer for over several decades; however, patient outcomes have not significantly improved over the years with conventional therapies. In recent years, this has caused researchers to look for a change in the status quo, and, the awareness of the human immune system, which has an intrinsic mechanism to control microbial pathogens and dysfunctional self-tissues, has triggered scientists to look for new modes of cancer therapy. Cancer Immunotherapy has become a major research field as a result of these efforts, gaining some recognition for notable breakthroughs in cancer patient prognosis. Frontiers in Cancer Immunology collectively...
Targeting the Post-irradiation Tumor Microenvironment in Glioblastoma Via Inhibition of CXCL12
Abstract: Radiotherapy is a mainstay in glioblastoma therapy as it not only directly targets tumor cells but also depletes the tumor microvasculature. The resulting intra-tumoral hypoxia initiates a chain of events that ultimately leads to re-vascularization, immunosuppression and, ultimately, tumor-regrowth. The key component of this cascade is overexpression of the CXC-motive chemokine ligand 12 (CXCL12), formerly known as stromal-cell derived factor 1 (SDF-1). We here review the role of CXCL12 in recruitment of pro-vasculogenic and immunosuppressive cells and give an overview on future and current drugs that target this axis
Glioblastoma: State of the Art and Future Perspectives
Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad “one-for-all” treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research.
Dendritic Cells in Cancer
It covers all aspects of DC generation, function, survival and antitumor activity in the tumor environment both in vivo and in experimental in vitro systems. The goal in focusing on a spectrum of issues related to DC in cancer is to provide an extensive and expansive review rather than a collection of independent analyses from different authors. Specific topics to be covered include analysis of DC behavior in the tumor microenvironment, including endogenous and exogenous DC, multiple DC populations, molecular pathways responsible for DC dysfunction, tumor-derived factors altering DC polarization and activation, mechanisms of DC alterations, and the role of DC in tumor escape from immune recognition and elimination. Furthermore, additional chapters provide extensive analysis of the consequences of cancer therapy on the DC system and how aging impacts DC function in the tumor microenvironment. Finally, chapters are included examining strengths and pitfalls of current methodologies for generating DC from cancer patients for therapeutic purposes and on the role of tumor-mediated modulation of the DC system in cancer immunotherapy.
AACR 2019 Proceedings: Abstracts 1-2748
American Association for Cancer Research 2019 Proceedings: Abstracts 1-2748 - Part A
Myeloid Derived Suppressor Cells as Disease Modulators
Myeloid Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that can suppress the function of multiple immune cells and in particular, T cells, through various mechanisms. MDSCs can be divided into two major subtypes based on their cell surface phenotype and morphology: polymorphonuclear MDSC (PMN-MDSC or G-MDSC) and monocytic MDSC (M-MDSC). Additional subtypes have been proposed, such as the early MDSC (e-MDSC) that lack both macrophage and granulocyte markers. There is still considerable ambiguity about the phenotype of these cells that corresponds to their immunosuppressive function and there are on-going challenges on how to identify, purify and/or p...
